Plate Nº 47 · recorded November 17, 2026

Health & Medicine ResearchReported finding

$12.6 Million NIH Grant to Track How Tuberculosis Keeps Outsmarting Us

A WashU-led team has won a $12.6 million, five-year NIH grant to work out why certain tuberculosis strains now dominate clinics worldwide — and how to outmaneuver them.

By Elena Vasquez3 min read677 words

In brief

  1. The NIH awarded a five-year, $12.6 million grant to a WashU Medicine-led tuberculosis research program.
  2. Tuberculosis causes an estimated 10.7 million cases and 1.2 million deaths annually, making it the world's deadliest infectious disease.
  3. The team has already identified TB variants that appear most often in patients worldwide.
  4. Sub-projects will examine TB evolution in patients with HIV and diabetes, conditions that raise TB risk.
  5. Standard TB antibiotic treatment lasts six months, a window in which the bacterium can adapt.
Stallings, Philips and collaborators to study evolution of tuberculosis
Plate Nº 47Stallings, Philips and collaborators to study evolution of tuberculosis — Kost9n4 / pixabay

A five-year, $12.6 million grant from the National Institute of Allergy and Infectious Diseases will fund a multi-institutional effort to understand how tuberculosis bacteria keep adapting to the humans they infect. Christina Stallings, PhD, and Jennifer Philips, MD, PhD, both Theodore and Bertha Bryan Professors of Environmental Medicine at WashU Medicine, lead the program, which spans eight institutions in total and pulls in disciplines from bacterial genome evolution to immunology.

The stakes are stark. Tuberculosis remains the world's deadliest infectious disease, causing an estimated 10.7 million cases and 1.2 million deaths every year. The bacterium, Mycobacterium tuberculosis, has evolved alongside humans for millennia, and it has adapted to every pressure we've thrown at it — including antibiotics, one of the newest threats to its survival.

"Tuberculosis has been with humans forever, and it's still a major deadly infection," Stallings said. "This project is looking at what's happening now in people with tuberculosis. What strains of bacteria are causing disease, and why have they emerged? Then, can we use that information to better treat these infections?"

What has the team already found?

By mining genetic sequences from TB strains collected from sick patients around the world, the researchers have already identified the specific bacterial variants that show up most often in clinics. The next step is figuring out why those variants dominate.

Three possibilities drive the work:

  • Are the variants better at evading a person's immune response?
  • Are they better at surviving a six-month course of antibiotics?
  • Are they simply better at spreading from one person to the next?

Answering those questions, the team argues, could point clinicians toward more targeted treatments. If a strain's advantage is antibiotic survival, for instance, that insight could reshape how doctors deploy existing drugs.

How do HIV and diabetes fit in?

A separate strand of the program studies how TB behaves in patients with HIV or diabetes, two conditions that raise a person's risk of developing the disease. Philips, a physician-scientist, leads the HIV project. She will test whether certain bacterial variants thrive or falter in people living with HIV — a group more susceptible to TB even when the virus is well controlled by medication.

Stallings is applying the same approach to diabetes. The comparison matters because it could reveal whether these common co-existing conditions quietly shape which TB strains take hold in patients.

The WashU-led team includes Dmitri Kotov, PhD, and Priya Pal, MD, PhD, both assistant professors of medicine in the Division of Infectious Diseases, alongside collaborators at six other institutions.

Who handles the data?

Makedonka Mitreva, PhD, the Gordon R. Miller Professor of Medicine at WashU Medicine, heads a dedicated bioinformatics core — in plain terms, a team that crunches complex biological data at scale. The core will analyze what researchers call multi-modal data: bacterial genetics and physiology alongside human immune responses, all in one integrated picture.

The work leans on a cloud-based data sharing and analytics platform built by the WashU Medicine Institute for Informatics, Data Science & Biostatistics.

"Putting together all the parts to profile the bacteria on multiple levels, profile the host immune response, incorporate these co-existing conditions and then integrate all that data is only possible because of the team we put together," Stallings said. "No single person would be able to do this on their own."

Why does this matter now?

Antibiotics changed the fight against TB, but the bacterium adapted to that pressure too, just as it adapted to centuries of human immune attack. Drug treatment still stretches over six months, a long window in which the bacteria can evolve workarounds.

The new program bets that understanding TB's current evolution in real patients — not just in the lab — will guide smarter treatment and prevention strategies. The findings are years away, and any clinical payoff remains speculative for now. But with 1.2 million deaths a year, the researchers say the bacterium's next move is worth anticipating. The grant gives them five years to map it.

via medicine.washu.edu (Source)

Filed under

  • tuberculosis
  • bacterial-evolution
  • antibiotic-resistance
  • nih-grants
  • infectious-diseases
Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Correspondent covering money, funding and market shifts around general science news at SciBeat.

503 articles

Nearby plates

« Previous articleNext article »